Antidepressant Drugs Transactivate TrkB Neurotrophin Receptors in the Adult Rodent Brain Independently of BDNF and Monoamine Transporter Blockade
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antidepressant drugs (ADs) have been shown to activate BDNF (brain-derived neurotrophic factor) receptor TrkB in the rodent brain but the mechanism underlying this phenomenon remains unclear. ADs act as monoamine reuptake inhibitors and after prolonged treatments regulate brain bdnf mRNA levels indicating that monoamine-BDNF signaling regulate AD-induced TrkB activation in vivo. However, recent findings demonstrate that Trk receptors can be transactivated independently of their neurotrophin ligands. METHODOLOGY: In this study we examined the role of BDNF, TrkB kinase activity and monoamine reuptake in the AD-induced TrkB activation in vivo and in vitro by employing several transgenic mouse models, cultured neurons and TrkB-expressing cell lines. PRINCIPAL FINDINGS: Using a chemical-genetic TrkB(F616A) mutant and TrkB overexpressing mice, we demonstrate that ADs specifically activate both the maturely and immaturely glycosylated forms of TrkB receptors in the brain in a TrkB kinase dependent manner. However, the tricyclic AD imipramine readily induced the phosphorylation of TrkB receptors in conditional bdnf⁻/⁻ knock-out mice (132.4±8.5% of control; P = 0.01), indicating that BDNF is not required for the TrkB activation. Moreover, using serotonin transporter (SERT) deficient mice and chemical lesions of monoaminergic neurons we show that neither a functional SERT nor monoamines are required for the TrkB phosphorylation response induced by the serotonin selective reuptake inhibitors fluoxetine or citalopram, or norepinephrine selective reuptake inhibitor reboxetine. However, neither ADs nor monoamine transmitters activated TrkB in cultured neurons or cell lines expressing TrkB receptors, arguing that ADs do not directly bind to TrkB. CONCLUSIONS: The present findings suggest that ADs transactivate brain TrkB receptors independently of BDNF and monoamine reuptake blockade and emphasize the need of an intact tissue context for the ability of ADs to induce TrkB activity in brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“a study by Rantamaki et al. (2011) showed a rapid action of imipramine on TrkB phosphorylation in either presence or absence of BDNF, suggesting that antidepressants do not require BDNF to activate TrkB, an effect that was independent of 5-HTT.”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Rantamaki et al. 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, the recent data suggesting that antidepressant could also directly transactivated TrkB (Rantamaki et al. 2011) point to this receptor as a main molecular target for treating depression.”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Rantamaki et al. 2011
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the tricyclic antidepressant imipramine (30 mg/kg i.p.) increased phosphorylation of TrkB (residue Y816) 30 minutes post-treatment in the PFC (Rantamäki et al., 2011).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Rantamäki et al., 2011
The cited source says what the claim attributes to it.
In the citing paper
“fluoxetine (30 mg/kg i.p.) also increased phosphorylation of TrkB one-hour post-treatment in the hippocampus of WT and serotonin transporter knockout mice”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Rantamäki et al., 2011
The cited source says what the claim attributes to it.
In the citing paper
“suggesting that antidepressants do not require BDNF to activate TrkB, an effect that was independent of 5-HTT.”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Rantamaki et al. 2011
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophins: Roles in Neuronal Development and Function
Huang, E. J., & Reichardt, L. F. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.677 · Cited by 4,394 · cited 1×
“Brainderived neurotrophic factor (BDNF) is the main endogenous ligand for TrkB [3], but recent evidence demonstrates that TrkB can also be transactivated independently of BDNF or other neurotrophins through neuromodulator receptors [6,7] and small molecules [8,9].”
BackgroundA Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375 · cited 1×
“Moreover, chronic, but not acute, AD treatment increases BDNF synthesis in the rodent brain [16,35].”
BackgroundNibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 2×
“Moreover, chronic, but not acute, AD treatment increases BDNF synthesis in the rodent brain [16,35].”
BackgroundNeurotrophins and Neuronal Plasticity
Thoenen, H. (1995) · Science · doi:10.1126/science.270.5236.593 · Cited by 1,927 · cited 1×
“differentiation, survival and plasticity throughout life [1–5].”
Neurotrophins as synaptic modulators
Poo, M.-M. (2001) · Nature Reviews Neuroscience · doi:10.1038/35049004 · Cited by 1,775 · cited 1×
“differentiation, survival and plasticity throughout life [1–5].”
Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression
Shirayama, Y., Chen, A. C.-H., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03251.2002 · Cited by 1,654
The yin and yang of neurotrophin action
Lu, B., Pang, P. T., & Woo, N. H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1726 · Cited by 1,356 · cited 1×
“Since it has recently been suggested that pro and mature forms of BDNF might have different capacities to activate TrkB [27], we investigated the effects of acute antidepressant treatment on proBDNF cleavage in brain.”
BackgroundNEUROTROPHINS AND SYNAPTIC PLASTICITY
McAllister, A. K., Katz, L. C., & Lo, D. C. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.295 · Cited by 1,337 · cited 1×
“differentiation, survival and plasticity throughout life [1–5].”
Sen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232 · cited 1×
“range upon a successful treatment with ADs [18,19].”
BackgroundIncreased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication
Chen, B., Dowlatshahi, D., MacQueen, G. M., Wang, J.-F., & Young, L. T. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01083-6 · Cited by 1,164 · cited 1×
“. Levels of BDNF are reduced in the brain and serum of depressed patients and the levels are returned back to normal range upon a successful treatment with ADs”
BackgroundNeurotrophins regulate dendritic growth in developing visual cortex
McAllister, A. K., Lo, D. C., & Katz, L. C. (1995) · Neuron · doi:10.1016/0896-6273(95)90171-x · Cited by 959 · cited 1×
“differentiation, survival and plasticity throughout life [1–5].”
BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders
Mattson, M. P., Maudsley, S., & Martin, B. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.08.001 · Cited by 942 · cited 1×
“serotonergic innervation [40,41].”
Antidepressant-like effect of brain-derived neurotrophic factor (BDNF)
Siuciak, J. A., Lewis, D. R., Wiegand, S. J., & Lindsay, R. M. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00169-4 · Cited by 841 · cited 1×
“BDNF injection and TrkB activation produce AD-like responses in rodents [36–38], while mice deficient of BDNF or with inhibited TrkB signaling do not respond to ADs in the forced swim test [13,17], the classical paradigm for AD effectiveness.”
BackgroundSaarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00349.2003 · Cited by 800 · cited 10×
“While all the different ADs readily induce TrkB autophosphorylation in rodent brain [13,15], neither these compounds nor”
BackgroundInfluentialInteraction between BDNF and Serotonin: Role in Mood Disorders
Martinowich, K., & Lu, B. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301571 · Cited by 793 · cited 1×
“serotonergic innervation [40,41].”
Rios, M., Fan, G., Fekete, C., Kelly, J., Bates, B., Kuehn, R., Lechan, R. M., & Jaenisch, R. (2001) · Molecular Endocrinology · doi:10.1210/me.15.10.1748 · Cited by 780 · cited 2×
“TK+ mutant [22,23], trkB knock-in [21], BDNF [28] and sert”
BackgroundMethodSelf-citationSairanen, M., Lucas, G., Ernfors, P., Castrén, M., & Castrén, E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3741-04.2005 · Cited by 763 · cited 1×
“brain [13,14].”
Bengel, D., Murphy, D. L., Andrews, A. M., Wichems, C. H., Feltner, D., Heils, A., Mössner, R., Westphal, H., & Lesch, K.-P. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.4.649 · Cited by 719
Self-citationMonteggia, L. M., Luikart, B., Barrot, M., Theobold, D., Malkovska, I., Nef, S., Parada, L. F., & Nestler, E. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.021 · Cited by 502 · cited 2×
“BDNF injection and TrkB activation produce AD-like responses in rodents [36–38], while mice deficient of BDNF or with inhibited TrkB signaling do not respond to ADs in the forced swim test [13,17], the classical paradigm for AD effectiveness.”
BackgroundActivation of Trk neurotrophin receptors in the absence of neurotrophins
Lee, F. S., & Chao, M. V. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061020198 · Cited by 482 · cited 4×
“Although BDNF is the main ligand of TrkB, recent evidence suggests that TrkB can also be activated independently of BDNF in neurons [6,8,9].”
BackgroundInfluentialTargeting the murine serotonin transporter: insights into human neurobiology
Murphy, D. L., & Lesch, K.-P. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2284 · Cited by 478 · cited 1×
“knock-out mice [46,47] were used in animal experiments.”
MethodSelf-citationNeurotrophic factors in Alzheimer’s disease: role of axonal transport
Schindowski, K., Belarbi, K., & Buée, L. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00378.x · Cited by 335 · cited 1×
“Abnormal TrkB receptor signaling has been linked to a number of central nervous system (CNS) diseases such as mood and memory disorders and addiction [10–12].”
BackgroundRantamäki, T., Hendolin, P., Kankaanpää, A., Mijatovic, J., Piepponen, P., Domenici, E., Chao, M. V., Männistö, P. T., & Castrén, E. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301345 · Cited by 305
Self-citationRajagopal, R., Chen, Z.-Y., Lee, F. S., & Chao, M. V. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0010-04.2004 · Cited by 257 · cited 2×
“This lower molecular weight protein might represent an immaturely glycosylated form of catalytic TrkB [24], as TrkB transactivation has been shown to coincide with accumulation of intracellular immaturely glycosylated TrkB species [6,7,25].”
BackgroundInteractions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain
Narita, N., Hashimoto, K., Tomitaka, S.-I., & Minabe, Y. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00254-3 · Cited by 254 · cited 1×
“Accumulating evidence has shown that ADs, including fluoxetine and tricyclic ADs, have several additional targets in cells such as neurotransmitter receptors [42,43], ion channels [44], Sigma-1 receptors [45] and adenosine Figure 2.”
BackgroundA Chemical-Genetic Approach to Studying Neurotrophin Signaling
Chen, X., Ye, H., Kuruvilla, R., Ramanan, N., Scangos, K. W., Zhang, C., Johnson, N. M., England, P. M., Shokat, K. M., & Ginty, D. D. (2005) · Neuron · doi:10.1016/j.neuron.2005.03.009 · Cited by 246
Shen, H.-W., Hagino, Y., Kobayashi, H., Shinohara-Tanaka, K., Ikeda, K., Yamamoto, H., Yamamoto, T., Lesch, K.-P., Murphy, D. L., Hall, F. S., et al. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300476 · Cited by 204 · cited 1×
“A 6–10 fold up-regulation of extracellular 5-HT levels in sert mice [34] did not regulate basal TrkB phosphorylation levels in hippocampus when compared to the wild-type controls (89.”
ResultSelf-citationDistinctive features of Trk neurotrophin receptor transactivation by G protein-coupled receptors
Lee, F. S., Rajagopal, R., & Chao, M. V. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00024-7 · Cited by 177 · cited 1×
“This lower molecular weight protein might represent an immaturely glycosylated form of catalytic TrkB [24], as TrkB transactivation has been shown to coincide with accumulation of intracellular immaturely glycosylated TrkB species [6,7,25].”
BackgroundKoponen, E., Võikar, V., Riekki, R., Saarelainen, T., Rauramaa, T., Rauvala, H., Taira, T., & Castrén, E. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.01.006 · Cited by 170 · cited 2×
“TK+) [22,23] with imipramine, we observed enhanced”
BackgroundTrkA glycosylation regulates receptor localization and activity
Watson, F. L., Porcionatto, M. A., Bhattacharyya, A., Stiles, C. D., & Segal, R. A. (1999) · Journal of Neurobiology · doi:10.1002/(sici)1097-4695(199905)39:2<323::aid-neu15>3.0.co;2-4 · Cited by 163 · cited 1×
“This lower molecular weight protein might represent an immaturely glycosylated form of catalytic TrkB [24], as TrkB transactivation has been shown to coincide with accumulation of intracellular immaturely glycosylated TrkB species [6,7,25].”
BackgroundJang, S.-W., Liu, X., Chan, C.-B., Weinshenker, D., Hall, R. A., Xiao, G., & Ye, K. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.05.010 · Cited by 144 · cited 4×
“Although BDNF is the main ligand of TrkB, recent evidence suggests that TrkB can also be activated independently of BDNF in neurons [6,8,9].”
BackgroundInfluentialThe effect of various centrally active drugs on adenosine uptake by the central nervous system
Phillis, J. W., & Wu, P. H. (1982) · Comparative Biochemistry and Physiology Part C Comparative Pharmacology · doi:10.1016/0306-4492(82)90082-x · Cited by 134 · cited 2×
“Furthermore, some ADs have been shown to acutely increase the extracellular levels of adenosine by reducing adenosine reuptake [31].”
BackgroundBrain-derived neurotrophic factor as a drug target for CNS disorders
Pezet, S., & Malcangio, M. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.5.391 · Cited by 132 · cited 1×
“Abnormal TrkB receptor signaling has been linked to a number of central nervous system (CNS) diseases such as mood and memory disorders and addiction [10–12].”
BackgroundKoponen, E., Rantamäki, T., Voikar, V., Saarelainen, T., MacDonald, E., & Castrén, E. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-005-8468-z · Cited by 125 · cited 1×
“BDNF injection and TrkB activation produce AD-like responses in rodents [36–38], while mice deficient of BDNF or with inhibited TrkB signaling do not respond to ADs in the forced swim test [13,17], the classical paradigm for AD effectiveness.”
BackgroundSelf-citationWiese, S., Jablonka, S., Holtmann, B., Orel, N., Rajagopal, R., Chao, M. V., & Sendtner, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705267104 · Cited by 117 · cited 1×
“Adenosine has been shown to transactivate TrkB receptors via adenosine-2A signaling in the absence of BDNF in vitro and in vivo [6,29] and to enhance TrkB signaling [30].”
BackgroundPires, V. A., Pamplona, F. A., Pandolfo, P., Fernandes, D., Prediger, R. D. S., & Takahashi, R. N. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32832a80bf · Cited by 84 · cited 1×
“similarly in mice pretreated with saline or active dose [32,33] of ZM241385 (Figure S3), suggesting that A2A receptors were not involved.”
BackgroundKoponen, E., Lakso, M., & Ċastrén, E. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.07.010 · Cited by 84 · cited 2×
“TK+) [22,23] with imipramine, we observed enhanced”
BackgroundMutual Regulation of Src Family Kinases and the Neurotrophin Receptor TrkB
Huang, Y. Z., & McNamara, J. O. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091041 · Cited by 68 · cited 2×
“Although BDNF is the main ligand of TrkB, recent evidence suggests that TrkB can also be activated independently of BDNF in neurons [6,8,9].”
BackgroundSebastião, A. M., & Ribeiro, J. A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00157.x · Cited by 66
Rantamäki, T., Knuuttila, J. E. A., Hokkanen, M., & Ċastrén, E. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.10.001 · Cited by 63
Self-citationtrkB-Receptor Activation Contributes to the Kainate-Induced Increase in BDNF mRNA Synthesis
Saarelainen, T., Vaittinen, S., & Ċastrén, E. (2001) · Cellular and Molecular Neurobiology · doi:10.1023/a:1012775808253 · Cited by 51 · cited 1×
“is tempting to speculate that this ligand-independent TrkB activation is contributing the AD-induced BDNF synthesis in brain [39] which further leads to BDNF-dependent TrkB phosphorylation after prolonged AD administration.”
BackgroundMiranda, C., Di Virgilio, M., Selleri, S., Zanotti, G., Pagliardini, S., Pierotti, M. A., & Greco, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110016200 · Cited by 51 · cited 1×
“Endo-H digestion produced a slight reduction in the molecule weight of the mature full-length TrkB, suggesting that the mature TrkB still contains immature-type glycan residues (Figure 2B), as also observed before for TrkA [26].”
ResultLobato, K. R., Binfaré, R. W., Budni, J., Rosa, A. O., Santos, A. R. S., & Rodrigues, A. L. S. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.01.012 · Cited by 50 · cited 2×
“similarly in mice pretreated with saline or active dose [32,33] of ZM241385 (Figure S3), suggesting that A2A receptors were not involved.”
BackgroundMethodLucchelli, A., Santagostino‐Barbone, M. G., Barbieri, A., Candura, S. M., & Tonini, M. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb13307.x · Cited by 49 · cited 1×
“Accumulating evidence has shown that ADs, including fluoxetine and tricyclic ADs, have several additional targets in cells such as neurotransmitter receptors [42,43], ion channels [44], Sigma-1 receptors [45] and adenosine Figure 2.”
BackgroundVesa, J., Krüttgen, A., & Shooter, E. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001641200 · Cited by 47
Targeting TrkB neurotrophin receptor to treat depression
Rantamäki, T., & Castrén, E. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.6.705 · Cited by 40 · cited 1×
“Abnormal TrkB receptor signaling has been linked to a number of central nervous system (CNS) diseases such as mood and memory disorders and addiction [10–12].”
BackgroundSelf-citationWyneken, Ú., Sandoval, M., Sandoval, S., Jorquera, F., González, I., Vargas, F., Falcon, R., Monari, M., & Orrego, F. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301052 · Cited by 35 · cited 1×
“ylated protein is detected by the same antibodies that demonstrate the phosphorylation of TrkB after AD treatment (Figure S1A–B) and has been detected following TrkB immunoprecipitation and hybridization to pTyr antibodies [13,20].”
BackgroundModulation of Ligand-gated Ion Channels by Antidepressants and Antipsychotics
Rammes, G., & Rupprecht, R. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0006-1 · Cited by 27 · cited 1×
“Accumulating evidence has shown that ADs, including fluoxetine and tricyclic ADs, have several additional targets in cells such as neurotransmitter receptors [42,43], ion channels [44], Sigma-1 receptors [45] and adenosine Figure 2.”
BackgroundAntidepressant Interactions with the NMDA NR1-1b Subunit
Raabe, R., & Gentile, L. N. (2008) · Journal of Biophysics · doi:10.1155/2008/474205 · Cited by 11 · cited 1×
“Accumulating evidence has shown that ADs, including fluoxetine and tricyclic ADs, have several additional targets in cells such as neurotransmitter receptors [42,43], ion channels [44], Sigma-1 receptors [45] and adenosine Figure 2.”
BackgroundEffects of the thalamus on the development of cerebral cortical efferentsin vitro
Lotto, R. B., Aitkenhead, A., & Price, D. J. (1999) · Journal of Neurobiology · doi:10.1002/(sici)1097-4695(199905)39:2<186::aid-neu3>3.0.co;2-g · Cited by 7
Cited by
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3505 · Cited by 743
Antidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.034 · Cited by 663
Self-citationBDNF mediates adaptive brain and body responses to energetic challenges
Marosi, K., & Mattson, M. P. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.10.006 · Cited by 568
“even activate TrkB independent of any effect on BDNF levels [65].”
BackgroundMoylan, S., Maes, M., Wray, N. R., & Berk, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.33 · Cited by 529
Liu, R.-J., Lee, F. S., Li, X.-Y., Bambico, F., Duman, R. S., & Aghajanian, G. K. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.030 · Cited by 403
Metadata
- Authors
- Rantamäki, T., Vesa, L., Antila, H., Di Lieto, A., Tammela, P., Schmitt, A., Lesch, K.-P., Rios, M., & Castrén, E.
- Affiliations
- University of Helsinki (FI)
- University of Würzburg (DE)
- Tufts University (US)
- Corresponding author
- Rantamäki, Tomi
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-06-07
- Volume
- 6
- Issue
- 6
- Pages
- e20567
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3110188
- OpenAlex
- W2019787596
- Cited by
- 124
- References
- 49
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 11 · 2021: 14 · 2020: 7 · 2019: 12 · 2018: 10 · 2017: 9 · 2016: 7 · 2015: 10 · 2014: 7 · 2013: 11 · 2012: 11
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by)
- Funders
- Helsingin Yliopisto
- Deutsche Forschungsgemeinschaft
- Suomen Kulttuurirahasto
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- antidepressants, TrkB receptor, brain-derived neurotrophic factor, receptor transactivation, monoamine reuptake inhibitors, serotonin transporter, imipramine, fluoxetine, citalopram, reboxetine, monoamine signaling, antidepressant mechanism
- MeSH terms
- Aging, Amitriptyline, Animals, Antidepressive Agents, Brain, Glycosylation, Imipramine, Mice, Inbred C57BL, Phosphorylation, Transcriptional Activation, Brain-Derived Neurotrophic Factor, Receptor, trkB, Serotonin Plasma Membrane Transport Proteins, Vesicular Monoamine Transport Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.